Blood and aqueous humor tumstatin concentrations associated with diabetic retinopathy

Diabetic Retinopathy (DR) is blood vessel damage in the retina that occurs due to long-standing Diabetes Mellitus (DM) [1]. It is estimated that 642 million people are to live with diabetes worldwide by 2040 [2]. Therefore, the global prevalence of diabetic retinopathy is also expected to increase signifi cantly over the past 20 years, due to the rise in the number of people diagnosed with diabetes [3]. However, incidence rate of DR might be decreased by aggressive control of hyperglycemia and hypertension [4,5]. As known in diabetes, increased blood sugar concentrations damage the blood vessels of the retina [6]. Retina is composed of blood vessels, nerve cells (neurons), and photoreceptor cells [7]. These damaged blood vessels leak fl uid, bleed, and do not provide adequate oxygen to the retina, leading to retinal ischemia (microaneurysms, hemorrhages, intraretinal microvascular abnormalities, cotton-woolspots, venous caliber abnormalities, and neovascularization [8,9]. As a result, vision loss can begin to due to vitreous hemorrhage and/or retinal detachment, macular edema, and retinal capillary nonperfusion and the retina is unable to function properly [10]. If it is fi nd out other underline mechanism of DR fully might delay at least the onset of diabetic retinopathy besides controlling blood sugar. As mentioned above, damage to the blood vessels deprives the retina of oxygen. Angiogenesis is new blood vessel formation from the preexisting vasculature, but Abstract


Introduction
Diabetic Retinopathy (DR) is blood vessel damage in the retina that occurs due to long-standing Diabetes Mellitus (DM) [1]. It is estimated that 642 million people are to live with diabetes worldwide by 2040 [2]. Therefore, the global prevalence of diabetic retinopathy is also expected to increase signifi cantly over the past 20 years, due to the rise in the number of people diagnosed with diabetes [3]. However, incidence rate of DR might be decreased by aggressive control of hyperglycemia and hypertension [4,5]. As known in diabetes, increased blood sugar concentrations damage the blood vessels of the retina [6]. Retina is composed of blood vessels, nerve cells (neurons), and photoreceptor cells [7]. These damaged blood vessels leak fl uid, bleed, and do not provide adequate oxygen to the retina, leading to retinal ischemia (microaneurysms, hemorrhages, intraretinal microvascular abnormalities, cotton-woolspots, venous caliber abnormalities, and neovascularization [8,9]. As a result, vision loss can begin to due to vitreous hemorrhage and/or retinal detachment, macular edema, and retinal capillary nonperfusion and the retina is unable to function properly [10]. If it is fi nd out other underline mechanism of DR fully might delay at least the onset of diabetic retinopathy besides controlling blood sugar. As mentioned above, damage to the blood vessels deprives the retina of oxygen. Angiogenesis is new blood vessel formation from the preexisting vasculature, but https://www.peertechz.com/journals/annals-of-systems-biology Citation: Oruc  uncontrolled neovascularization is associated with a number of pathological disorders including rheumatoid arthritis and diabetic retinopathy [11,12]. Angiogenesis might help damaged blood vessels in order provide the oxygen and other essential nutrients in the retinal ischemia [12]. Recent studies have suggested a connection between tumstatin involved in newly formed vessel network in a corneal neovascularization [13]. The role of Tumstatin in DR is unknown and remains an essential research interest until now. There might be a link between Tumstatin, cataract, DM+ cataract and DR. Therefore, the involvement of Tumstatin in the progression of DR has yet to be elucidated Tumstatin (an angiogenesis inhibitor) is a protein with a molecular weight of 28 kDa [14]. This protein belongs to Growth Factor (VEGF) and progression of vessel formation [14].
Also, administration of tumstatin has been demonstrated to reduce glomerular hypertrophy, hyperfi ltration, and albuminuria in streptozotocin-induced diabetic mice [16].
Monocyte/macrophage accumulation was also inhibited by tumstatin peptide [16,17]. Based on above given information it is possible that tumstatin may have a decisive role in a number of ocular pathologies including retinopathy of prematurity and diabetic retinopathy. Therefore, purpose of this was to determine levels of tumstatin in the blood and A queous humor (Aq) of patients with diabetes mellitus and cataract with and without diabetic retinopathy.  [18] and according to the ADA guidelines [19] and cataract diagnosis was done by ophthalmologists [20].

Materials and methods
Biological fl uids (blood and aqueous humor) were obtained while Phaco surgery was performed between January 2016 and December 2019 as indicated in detail in our previously published article [10]. Blood and aqueous humor are transferred to the archives and stored -40  C for further analysis as explained earlier [21]. Tumstatin concentrations were analyzed from our biological fl uid archives while other parameters were obtained from patient's fi les. Fasting blood glucose and triglycerides levels were measured with standard methods by biochemistry analyzer. The Body Mass Index (BMI) was calculated by dividing the body weight in kilograms to the square of the height in meters [body weight/height 2 ].

Quantitation of blood and aqueous humor tumstatin
Tumstatin measurement is carried out by enzyme-linked immunosorbent assays (Bioassay Technology Laboratory catalog no: E4234Hu Shanghai, CHINA) in blood and aqueous humor (ELISA). To determine whether the Tumstatin ELISA kit accurately measured the parameters in our samples, the detectability and reliability of this assay was assessed in our laboratory according to previously published procedure [21]. The measurement range of the human Tumstatin kit was 0.2-70 ng/mL, the intraassay Coeffi cient of Variation (CV) value, <8%, and the interassay CV value , <10%. Aq samples were diluted with phosphate-buffered saline (pH 7.4 at a 1:2 ratio); Plates were washed using the automatic washer Bio-Tek ELX50 (BioTek Instruments, Winooski). Optical density values were measured at a wavelength of 450 nm using the spectrophotometric microplate reader ChroMate P4300 (Awareness Technology Instruments, FL).

Statistical analyses
The mean comparisons between groups were performed using Statistical Package for the Social Sciences version 22.0 (SPSS Inc., Chicago, IL, USA). The signifi cance level was set at p<0.05. Kruskal-Wallis test was used for comparison of means between groups for all the parameters.

Results
The demographic characteristics and some biochemical parameters of the participants are seen in Table 1.The average age of the cataract, DM and DR patients in this study was 56.10±3.38, 57.40±3.10 and 59.38±2.83 years, respectively. It was also found that for blood samples, the intraassay CV value and interassay CV values were 8%, and 10%, respectively. For aqueous humor samples, the intraassay CV value and interassay CV values were 10%, and 12%, respectively. Recovery results of the kits ranged from 81% to 129%. Linearity in the measurements was observed at dilutions of 1:2, 1:4, 1:8, and 1:16. Based on our tests, the tumstatin ELISA kit for aqueous humor samples were as sensitive as blood samples. DR is also more common in women than men.
Blood tumstatin levels were signifi cantly elevated in DR patients with cataract as compared with diabetic subjects with cataract (without DR) and patients with only cataract (control) having p values; 0.009, 0.000, respectively as indicated in Figure  1. Aqueous humor tumstatin levels were also signifi cantly elevated in DR patients with cataract as compared with diabetic subjects with cataract (without DR) and patients with only cataract (control) having p values; 0.041, 0.000, respectively as indicated in Figure 1. Aqueous humor tumstatin levels were higher than that of blood tumstatin levels as seen Figure 1.

Discussion
In the present study, we fi rst time demonstrate that tumstatin signifi cantly increased in the blood and Aq of Citation: Oruc  patients with DM + cataract, with DR+ cataract when compared with patients bearing only cataract. It was also observed that Tumstatin signifi cantly increased in the blood and Aq of patients with DR + cataract than that of patients with DM + cataract. The rise in tumstatin in the blood and aqueous humor might lead to compensatory mechanisms aimed at ameliorating alterations in the early stage of diabetes. Supporting this notion it has been showed that the therapeutic effect of tumstatin in ameliorating alterations in the early stage of diabetic nephropathy induced by Streptozotocin (STZ) in mice [16].
These effects of Tumstatin were supposed to be mediated through downregulation of pro-angiogenic factors and Endothelial Growth Factors (VEGF). Increased expression of VEGF has been reported in diabetic retinopathy [22]. Tumstatin also inhibits in vivo neovascularization induced by VEGF, suggesting its potential therapeutic effi cacy in diabetic nephropathy [16], since upregulation of VEGF has been reported in diabetic nephropathy [22].
Furthermore, administration of anti-VEGF neutralizing antibodies has been indicated to fall hyperfi ltration, albuminuria, and glomerular hypertrophy in diabetic rats or mice [23,24]. Also, it has been reported that treatment with tumstatin remarkably suppressed glomerular hypertrophy, hyper fi ltration, and urinary albumin excretion as well as the accumulation of mesangial matrix [16]. That study was suggestive of the involvement of angiogenesis in the development of glomerular alterations in diabetic nephropathy similar to diabetic retinopathy [25].
The level of tumstatin was signifi cantly high in aqueous humor as compared with the level of tumstatin in the blood. The marked increase of tumstatin in aqueous humor suggests that aqueous humor might be another source of tumstatin and considering simultaneous upregulation with blood and that might pass to aqueous humor via blood tumstatin saturation and possibly associated with diabetery disease response. These results suggest the biological function of tumstatin peptide as an antiangiogenic peptide in a DR similar to its effi cacy reported on diabetic nephropathy model [26].
Diabetic Retinopathy (DR) patients have high levels of tumstatin. So that blood and aqueous humor tumstatin can probably be considered as one of the best biological markers refl ecting diabetic retinopathy compared with control. The increased amount of tumstatin in patient with diabetic retinopathy must be taken into account and the increased amount of tumstatin might be associated with pathophysiology of diabetic retinopathy. If neovascularization contributes signifi cantly to the pathogenesis of diabetic retinopathy, then tumstatin (antiangiogenic) therapy might be a novel approach to retard the progression of diabetic retinopathy in the future.